BioSpace News Archive

Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced the appointment of Dr. Goran Ando to its Board of Directors, replacing Amir Nashat, effective April 24, 2020. Amir will continue to serve in an advisory capacity to Selecta. “The addition of Dr. Ando to our Board means that Selecta

Increasing benefit reported from patients with first line Non-Small Cell Lung Cancer (NSCLC): º Improving Overall Response Rate (ORR) of 53% (earlier data indicated 47%) º Improving Progression free Survival (PFS) now at more than 8 months, median PFS not yet reached º 71% patients with tumour shrinkage Encouraging results also from patients with second line Head and Neck Squamous Cell Carcinoma (HNSCC): º ORR of 33% (consistent with earlier data) without substantial additional

All-Digital AI-Powered Platform to Reduce Human Error, Connect Remote Experts, Increase Diagnostic Lab Reliability and Efficiency

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the Company and the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), the Department of Defense’s lead laboratory for medical biological defense research, have entered into a Cooperative Research and Development Agreement (CRADA). The purpose of the CRADA is to jointly identify antisense ol

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that it has released its annual letter to shareholders. In the shareholder letter Angelos Stergiou, MD, ScD h.c., SELLAS’ President & Chief Executive Officer, addresses the Company’s product development, ant

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointment of Brian A. Walter , Ph.D., as Vice President of Regulatory Affairs. Dr. Walter will provide oversight for all U.S. and international regulatory strate

CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, has appointed Richard J. Gregory , PhD to the position of Acting Chief Scientific Officer. Dr.

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the annual report for 2019 is now available on the company’s website. The report summarizes the company’s business operations, strategy and financial results. The annual report is available as a PDF version on the company’s website below; www.oncopeptides.com / Inve

As April and National Occupational Therapy Month come to a close, The University of St. Augustine for Health Sciences wants to recognize the unique ways Occupational Therapists are helping people during the COVID-19 Pandemic.

Production and launch of the test kit RT-PCR COVID-19 Thai Duong will take place at the end of April 2020 and are carried out by Vietnamese science and technology company SUNSTAR Joint Stock Company.